专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004028450A2 PROCESS OF MAKING PHENYLPYRAZOLES USEFUL AS SELECTIVE 5HT2A MODULATORS AND INTERMEDIATES THEREOF 审中-公开
标题翻译：制备苯乙烯作为选择性5HT2A调节剂及其中间体的方法
公开(公告)号：WO2004028450A2
公开(公告)日：2004-04-08
申请号：PCT/US2003/029736
申请日：2003-09-22
申请人： ARENA PHARMACEUTICALS, INC. , HORNS, Stefan , RAY, Max , TEEGARDEN, Bradley , DROUET, Keith , FEICHTINGER, Konrad , ELWELL, Katie
发明人： HORNS, Stefan , RAY, Max , TEEGARDEN, Bradley , DROUET, Keith , FEICHTINGER, Konrad , ELWELL, Katie
IPC分类号： A61K
CPC分类号： C07D231/16
摘要： The present invention relates to a process for making certain selective 5HT 2A modulators of Formula (I) and the intermediates thereof: Formula (I) wherein R l -R 7 are described. Compounds of Formula (I) are useful in the prophylaxis or treatment of 5HT 2A mediated diseases, such as, 5HT 2A mediated platelet aggregation, asthma, agitation, degenerative diseases of the CNS and the like.
摘要翻译：本发明涉及制备式（I）的某些选择性5HT2A调节剂及其中间体的方法：其中描述了R 1 -R 7的式（I）。式（I）的化合物可用于预防或治疗5HT2A介导的疾病，例如5HT2A介导的血小板聚集，哮喘，激动，CNS退行性疾病等。

2. 发明申请

WO2003062206A3 SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO 审中-公开
公开(公告)号：WO2003062206A3
公开(公告)日：2003-07-31
申请号：PCT/US2003/002059
申请日：2003-01-23
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , DROUET, Keith , JAYAKUMAR, Honnappa , THOMSEN, William , MAFFUID, Paul , ELWELL, Katie , FOSTER, Richard , LAWLESS, Michael , LIU, Qian , SMITH, Julian , FEICHTINGER, Konrad
发明人： TEEGARDEN, Bradley , DROUET, Keith , JAYAKUMAR, Honnappa , THOMSEN, William , MAFFUID, Paul , ELWELL, Katie , FOSTER, Richard , LAWLESS, Michael , LIU, Qian , SMITH, Julian , FEICHTINGER, Konrad
IPC分类号： C07D231/16
摘要： The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Formula (I): Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia and related disorders. The present invention also relates to the method of prophylaxis or treatment of 5-HT 2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

3. 发明申请

WO2003062206A2 SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：用于预防和治疗相关疾病的5-HT2A丝氨酸受体的小分子调节剂
公开(公告)号：WO2003062206A2
公开(公告)日：2003-07-31
申请号：PCT/US2003/002059
申请日：2003-01-23
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , DROUET, Keith , JAYAKUMAR, Honnappa , THOMSEN, William , MAFFUID, Paul , ELWELL, Katie , FOSTER, Richard , LAWLESS, Michael , LIU, Qian , SMITH, Julian , FEICHTINGER, Konrad
发明人： TEEGARDEN, Bradley , DROUET, Keith , JAYAKUMAR, Honnappa , THOMSEN, William , MAFFUID, Paul , ELWELL, Katie , FOSTER, Richard , LAWLESS, Michael , LIU, Qian , SMITH, Julian , FEICHTINGER, Konrad
IPC分类号： C07D231/16
CPC分类号： C07D231/12 , C07D231/14 , C07D231/16 , C07D401/12 , C07D409/04
摘要： The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Formula (I): Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia and related disorders. The present invention also relates to the method of prophylaxis or treatment of 5-HT 2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.
摘要翻译：本发明涉及式（I）的某些吡唑衍生物及其药物组合物，其调节5-HT2Ba5-5羟色胺受体的活性。式（I）：其化合物及其药物组合物涉及可用于预防或治疗减少血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，降低血凝块形成风险的方法，哮喘或其症状，激动或症状，行为障碍，药物诱导的精神病，兴奋性精神病，杜勒氏综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症和NOS精神分裂症及相关障碍。本发明还涉及与单独或一起施用的多巴胺D2受体拮抗剂如氟哌啶醇组合预防或治疗5-HT2,5α血清素受体介导的病症的方法。

4. 发明申请

WO2007136703A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A丝氨酸蛋白受体的调节剂的主要氨基酸及其衍生物
公开(公告)号：WO2007136703A1
公开(公告)日：2007-11-29
申请号：PCT/US2007/011834
申请日：2007-05-17
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , CHAPMAN, Dennis , CHOI, Juyi , FEICHTINGER, Konrad , HAN, Sangdon , JAYAKUMAR, Honnappa , TRAN, Thuy-Anh , XU, Jingdong , ZOU, Ning
发明人： TEEGARDEN, Bradley , CHAPMAN, Dennis , CHOI, Juyi , FEICHTINGER, Konrad , HAN, Sangdon , JAYAKUMAR, Honnappa , TRAN, Thuy-Anh , XU, Jingdong , ZOU, Ning
IPC分类号： C07D231/12 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61K31/415 , A61K31/4155 , A61P7/00
CPC分类号： A61K31/415 , C07D231/12 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及调节5-HT 2A 2 5-羟色胺受体活性的某些式（Ia）化合物及其药物组合物。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，以及睡眠障碍，睡眠障碍，糖尿病性精神病，精神病性精神病，精神病性精神病，精神病性精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与分开或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

5. 发明申请

WO2006055734A2 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的3-苯基 - 吡唑衍生物
公开(公告)号：WO2006055734A2
公开(公告)日：2006-05-26
申请号：PCT/US2005/041726
申请日：2005-11-17
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , XIONG, Yifeng , STRAH-PLEYNET, Sonja , JAYAKUMAR, Honnappa , DOSA, Peter I. , FEICHTINGER, Konrad , CASPER, Martin , LEHMANN, Juerg , JONES, Robert M. , UNETT, David J.
发明人： TEEGARDEN, Bradley , XIONG, Yifeng , STRAH-PLEYNET, Sonja , JAYAKUMAR, Honnappa , DOSA, Peter I. , FEICHTINGER, Konrad , CASPER, Martin , LEHMANN, Juerg , JONES, Robert M. , UNETT, David J.
CPC分类号： C07D231/12 , A61K31/5377 , C07D231/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D487/08
摘要： The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及式（Ia）的某些3-苯基 - 吡唑衍生物及其药物组合物，其调节5-HT 2A / 5-羟色胺受体的活性。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，降低血块形成风险，哮喘或其症状，激动或症状，行为障碍，药物诱导的精神病，兴奋性精神病，吉列斯图雷特综合征，躁狂症，有机或非精神病精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，以及睡眠障碍，睡眠障碍，糖尿病相关病症，进行性多灶性脑白质病等。本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体介导的病症的方法。

6. 发明申请

WO2007136875A2 ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为用于治疗相关疾病的5-HT2A硒同位素受体的调节剂的乙酰胺衍生物
公开(公告)号：WO2007136875A2
公开(公告)日：2007-11-29
申请号：PCT/US2007/012230
申请日：2007-05-17
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , FEICHTINGER, Konrad , STRAH-PLEYNET, Sonja , ULMANN, Brett , XIONG, Yifeng
发明人： TEEGARDEN, Bradley , FEICHTINGER, Konrad , STRAH-PLEYNET, Sonja , ULMANN, Brett , XIONG, Yifeng
CPC分类号： C07D231/16 , C07D231/12 , C07D401/12 , C07D405/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及调节5-HT 2A 2 5-羟色胺受体活性的某些式（Ia）化合物及其药物组合物。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，以及睡眠障碍，睡眠障碍，糖尿病性精神病，精神病性精神病，精神病性精神病，精神病性精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与分开或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

7. 发明申请

WO2007136680A2 ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：其他作为5-HT2A丝氨酸受体调节剂的二级氨基酸和衍生物，用于治疗与相关疾病有关的疾病
公开(公告)号：WO2007136680A2
公开(公告)日：2007-11-29
申请号：PCT/US2007/011789
申请日：2007-05-17
申请人： ARENA PHARMACEUTICALS, INC. , TEEGARDEN, Bradley , CHAPMAN, Dennis , DECAIRE, Marc , DOSA, Peter, I. , FEICHTINGER, Konrad , JAYAKUMAR, Honnappa , STRAH-PLEYNET, Sonja , TRAN, Thuy-Anh , XU, Jingdong
发明人： TEEGARDEN, Bradley , CHAPMAN, Dennis , DECAIRE, Marc , DOSA, Peter, I. , FEICHTINGER, Konrad , JAYAKUMAR, Honnappa , STRAH-PLEYNET, Sonja , TRAN, Thuy-Anh , XU, Jingdong
IPC分类号： C07D413/12 , C07D231/12 , C07D231/16 , C07D403/12 , C07D411/12 , A61K31/42 , A61K31/4192 , A61K31/427
CPC分类号： C07D231/12 , A61K31/415 , C07D207/335 , C07D207/34 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病，精神病，相关疾病，进行性多灶性脑白质病等。本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

8. 发明申请

WO2009023253A2 IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为5-HT2A血清素受体调节剂的咪唑并[l，2-α]吡啶衍生物，用于治疗与其相关的病症
公开(公告)号：WO2009023253A2
公开(公告)日：2009-02-19
申请号：PCT/US2008/009740
申请日：2008-08-14
申请人： ARENA PHARMACEUTICALS INC. , XIONG, Yifeng , FEICHTINGER, Konrad , REN, Albert, S. , ULMANN, Brett
发明人： XIONG, Yifeng , FEICHTINGER, Konrad , REN, Albert, S. , ULMANN, Brett
IPC分类号： C07D471/04 , A61K31/437 , A61P25/20
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/0053 , A61K31/5377 , C07D471/04
摘要： rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
摘要翻译：式（Ia）的咪唑并[1,2-a]吡啶衍生物及其调节5-HT 2A受体5-羟色胺受体活性的药物组合物。其化合物和药物组合物涉及用于治疗失眠，睡眠障碍，睡眠障碍和相关睡眠障碍，血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房纤颤，血栓形成，哮喘或症状的方法激动或其症状，行为障碍，药物诱发的精神病，兴奋性精神病，吉勒斯德拉图雷特综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，NOS精神分裂症和相关障碍，相关疾病，进行性多灶性白质脑病等。本发明还涉及与分开或一起施用的其它药剂联合治疗5-HT 2A受体5-羟色胺受体介导的病症的方法。

9. 发明申请

WO2017023679A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： 5-HT2C受体激动剂及其组合物和使用方法
公开(公告)号：WO2017023679A1
公开(公告)日：2017-02-09
申请号：PCT/US2016/044426
申请日：2016-07-28
申请人： ARENA PHARMACEUTICALS, INC.
发明人： LEHMANN, Juerg , FEICHTINGER, Konrad , REN, Albert S. , SEMPLE, Graeme
IPC分类号： C07D223/16 , C07D223/32 , C07D491/052 , A61K31/55 , A61P3/04
CPC分类号： C07D223/16 , C07D223/32 , C07D491/052
摘要： Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
摘要翻译：在一些实施方案中提供了调节5-HT 2C受体活性的式A定义的化合物。在一些实施方案中还提供了一些方法，例如用于体重管理，诱导饱腹感和减少食物摄取，以及用于预防和治疗肥胖，抗精神病药物引起的体重增加，2型糖尿病，Prader-Willi综合征，烟草/尼古丁依赖性，吸毒成瘾，酒精成瘾，病态赌博，奖励缺乏综合征和性成瘾），强迫症频谱障碍和冲动控制障碍（包括指甲和精神病），睡眠障碍（包括失眠，分散的睡眠结构和慢性紊乱睡眠障碍），尿失禁，精神障碍（包括精神分裂症，神经性厌食症和神经性贪食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森综合征和抗精神病诱发的运动障碍），高血压，血脂异常，非酒精性脂肪性肝病，肥胖相关性肾病和睡眠呼吸暂停。

10. 发明申请

WO2015066344A1 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： 5-HT2C受体激动剂及其组合物和使用方法
公开(公告)号：WO2015066344A1
公开(公告)日：2015-05-07
申请号：PCT/US2014/063191
申请日：2014-10-30
申请人： ARENA PHARMACEUTICALS, INC.
发明人： SEMPLE, Graeme , BEHAN, Dominic P. , FEICHTINGER, Konrad , GLICKLICH, Alan , GROTTICK, Andrew J. , KAM, Maria Matilde Sanchez , KASEM, Michelle , LEHMANN, Juerg , REN, Albert S. , SCHRADER, Thomas O. , SHANAHAN, William R. , WONG, Amy Siu-Ting , ZHU, Xiuwen
IPC分类号： A61K31/5517 , C07D487/06 , A61P25/30 , A61P25/34 , A61P3/04
CPC分类号： A61K31/5517 , C07D487/06
摘要： Provided are 5-HT 2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT 2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT 2C receptor agonist, optionally in combination with a supplemental agent.
摘要翻译：提供5-HT 2C受体激动剂。还提供了用于体重管理，诱导饱腹感和减少食物摄入以及预防和治疗肥胖，抗精神病药物引起的体重增加，2型糖尿病，Prader-Willi综合征，烟草/尼古丁依赖，药物成瘾，酒精成瘾，病理学赌博，奖励缺陷综合征和性成瘾），强迫性频谱障碍和冲动控制障碍（包括指甲和精神病），睡眠障碍（包括失眠，零散睡眠结构和慢波睡眠障碍），尿失禁，精神障碍（包括精神分裂症，神经性厌食和神经性贪食），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森综合征和抗精神病诱发的运动障碍），高血压，血脂异常，非酒精性脂肪性肝病，相关的肾脏疾病和睡眠呼吸暂停。还提供了包含选择性5-HT 2C受体激动剂，任选地与补充剂组合的组合物，以及降低试图降低吸烟频率的个体吸烟的频率的方法; 协助在试图停止或减少使用烟草制品的个人中停止或减少使用烟草制品; 协助戒烟和预防相关体重增加; 控制一个企图停止吸烟的个人与戒烟相关的体重增加; 减轻试图戒烟的个人与戒烟相关的体重增加; 在试图治疗尼古丁依赖，成瘾和/或戒断的个体中治疗尼古丁依赖，成瘾和/或戒断; 或减少试图停止尼古丁使用的个体复发使用尼古丁的可能性，包括施用选择性的5-HT 2C受体激动剂，任选地与补充剂组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式